VC-backed Moderna Therapeutics goes public
Cambridge, Massachusetts-based Moderna Therapeutics, a developer of messenger RNA therapeutics and vaccines, has raised $604.3 million for its IPO after pricing its over 26.2 million shares at $23 per share. The stock began trading December 7, 2018 on the NASDAQ under the ticker symbol "MRNA." Morgan Stanley, Goldman Sachs and J.P. Morgan are the lead underwriters. Moderna's pre-IPO backers include Sequoia Capital China, Fidelity Management & Research Company, Pictet, Viking Global Investors, ArrowMark Partners and Alexandria Venture Investments.
7 December 2018•3 mins read
